Takano T, Masuda N, Ito M, Inoue K, et al. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Res Treat 2024 May 20. doi: 10.1007/s10549-024-07333.
PMID: 38767786